OGT2115
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406968

CAS#: 853929-59-6

Description: OGT-2115 is a heparanase inhibitor (IC50 = 0.4 μM). Heparanase inhibitors suppress breast cancer cell invasion and migration induced by ER stress, and provide a strong rationale for the development of heparanase-based therapeutics for the prevention of metastasis induced by chemotherapeutic reagents.


Price and Availability

Size
Price

1mg
USD 220
Size
Price

10mg
USD 350
Size
Price

OGT 2115, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406968
Name: OGT2115
CAS#: 853929-59-6
Chemical Formula: C24H16BrFN2O4
Exact Mass: 494.0277
Molecular Weight: 495.3044
Elemental Analysis: C, 58.20; H, 3.26; Br, 16.13; F, 3.84; N, 5.66; O, 12.92


Synonym: OGT -115; OGT2115; OGT2115.

IUPAC/Chemical Name: 2-[4-[[3-(4-Bromophenyl)-1-oxo-2-propenyl]amino]-3-fluorophenyl]-5-benzoxazoleacetic acid

InChi Key: LKBXWNYXDMSFQU-ONNFQVAWSA-N

InChi Code: InChI=1S/C24H16BrFN2O4/c25-17-6-1-14(2-7-17)4-10-22(29)27-19-8-5-16(13-18(19)26)24-28-20-11-15(12-23(30)31)3-9-21(20)32-24/h1-11,13H,12H2,(H,27,29)(H,30,31)/b10-4+

SMILES Code: O=C(O)CC1=CC=C(OC(C2=CC=C(NC(/C=C/C3=CC=C(Br)C=C3)=O)C(F)=C2)=N4)C4=C1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Shimada K, Anai S, Fujii T, Tanaka N, Fujimoto K, Konishi N. Syndecan-1
(CD138) contributes to prostate cancer progression by stabilizing
tumour-initiating cells. J Pathol. 2013 Dec;231(4):495-504. doi:
10.1002/path.4271. PubMed PMID: 24549646.

2: Li Y, Liu H, Huang YY, Pu LJ, Zhang XD, Jiang ZW, Jiang CC. [Effects of
cisplatin combined with heparanase inhibitor on proliferation and invasion of
human nasopharyngeal carcinoma cells]. Yao Xue Xue Bao. 2013 Apr;48(4):609-14.
Chinese. PubMed PMID: 23833953.

3: Li Y, Liu H, Huang YY, Pu LJ, Zhang XD, Jiang CC, Jiang ZW. Suppression of
endoplasmic reticulum stress-induced invasion and migration of breast cancer
cells through the downregulation of heparanase. Int J Mol Med. 2013
May;31(5):1234-42. doi: 10.3892/ijmm.2013.1292. PubMed PMID: 23467544.